With negative FDA panel vote, AstraZeneca's Lynparza looks set for narrow nod in prostate cancer

With negative FDA panel vote, AstraZeneca's Lynparza looks set for narrow nod in prostate cancer

Source: 
Fierce Pharma
snippet: 

A panel of external experts for the FDA voted 11 to 1 in support of a narrow approval for AstraZeneca and Merck’s Lynparza, used in tandem with Johnson & Johnson’s Zytiga and a corticosteroid, in metastatic castration-resistant prostate cancer (mCRPC).